Adherium Ltd. · ASX:ADR
Adherium — Shareholder Meeting (November 2025)
30 slides from Adherium's shareholder meeting presentation, Nov 18, 2025
Slide 1: A New Frontier In Respiratory Care
ASX: ADR A New Frontier In Respiratory Care November 2025
Slide 2: Disclaimer and Forward-Looking Statement
Disclaimer and Forward-Looking Statement The material contained herein is of a general nature & has only been prepared as a. the possible delays in & the outcome of product development a presentation aid. This presentation does NOT contain all of the information that may be required for evaluating A
Slide 3: Executive Summary
Executive Summary Market Opportunity of Patients Ground-breaking Technology Secured Access to >1M with Respiratory Diseases Adherium is the world leading respiratory COPD/Asthma Patients exceeds 40M in US alone health technology company with over 200,000 Adherium has contracts with leading devices s
Slide 4: 40M Americans live with chronic respiratory disease
40M Americans live with chronic respiratory disease Non-adherence with medications is a primary cause of avoidable hospitalisations, emergency department visits and billions in costs to the healthcare system
Slide 5: What are COPD and Asthma?
What are COPD and Chronic Obstructive Pulmonary Disease (COPD) Asthma? • Chronic Obstructive Pulmonary Disease While COPD and asthma • Long-term lung disease that slowly gets worse over time are different conditions, • Common types: chronic bronchitis (“smoker’s cough”) and the treatments – like emp
Slide 6: In the United States, COPD costs $59.6B
In the United States, COPD costs $59.6B with an average cost Prescribed Pharma of ~$18k per severe 28% Hospital 29% Inpatient patient1,2 Nearly half of costs are COPD direct tied to hospitalisations cost breakdown and ED visits by type3 General 10% 10% Admin Ambulatory 13% 10% Nursing Emergency Care
Slide 7: COPD flare ups spiral after the first episode
COPD flare ups (exacerbations) spiral after the first episode4 One flare up can significantly reduce lung function, setting off a chain of flare ups, further lung decline, and costly hospitalisations. Stopping the first flare up can prevent many future events and avoid multiple costly hospitalisatio
Slide 8: Flare ups irreversibly reduce lung function and raise cardiovascular risk
Flare ups irreversibly COPD reduce lung function Worsening Symptoms and nearly 4x the Increased breathlessness and frequent productive cough = higher risk of exacerbations risk of cardiovascular events, leading to +79% risk of death COPD Cardiopulmonary Flare up/Exacerbations Events and COPD Exacerb
Slide 9: If COPD patients are 60% or greater adherent, hospitalisation risk drops
If COPD patients are Reduction to the Risk of Hospitalisations Based on Levels of Adherence in COPD 60% or greater adherent to their 80-100% medications, their risk Adherence 51% of hospitalisation drops ~50%12 60-80% Adherence Most patients demonstrate 48% adherence of 20% or less 40-60% Adherence
Slide 10: Adherium Connected Respiratory Ecosystem
Adherium Connected Respiratory Ecosystem Adherium’s connected Smartinhalers power an end-to-end ecosystem that captures real-world respiratory data, transforms it into actionable insights, and enables clinicians, coaches, and patients to work in sync — improving adherence, technique, and long-term o
Slide 11: Building a Scalable Revenue Pathway: From RPM Today to Value-Based Care Tomorrow
Building a Scalable Revenue Pathway: From RPM Today to Value-Based Care Tomorrow Fee For Service Value Based Care via Remote Patient Monitoring (RPM) via US Payers RPM infrastructure and adherence data create the Volume Small Outcomes Large foundation for scalable, Based Scale Based Scale outcomes-b
Slide 12: Preparing for US Payor Value-Based Care Contracts
Adherium is preparing for the next inflection point: US Payor Value-Based Care Contracts COMPELLING ESTABLISHED CRITICAL MASS US PAYER COST SAVINGS INFRASTRUCTURE EXPERIENCE READY IMH data Scalable 4000 active patients EOY positioned to unleash cost savings Adherium | A new frontier in respiratory c
Slide 13: The iCARE respiratory care program
The iCARE respiratory care program with the Hailie® Smartinhaler® First-of-its-kind program demonstrating how continuous digital monitoring and care can drive patient adherence and lower costs due to avoidable hospitalisations and emergency department visits
Slide 14: Landmark independent program demonstrating robust clinical outcomes
Landmark independent program demonstrating robust clinical outcomes 848 patients tracked with some on for over 14-months+ (program ongoing) Physician-driven enrollment – very broad selection criteria Independent clinical care program, no vendor-paid monitoring or incentives Designed and driven by In
Slide 15: iCARE patients demonstrated 67% adherence in COPD and 64% in asthma
iCARE patients demonstrated 67% adherence in COPD and 64% in asthma 1.5-3x industry standard norms of 20-40% Improved adherence compared to reported “norms” 13-16 70% 67% 60% 64% 50% 40% 30% 20% 22% 20% Benchmark 10% norm adherence 0% iCARE adherence Asthma COPD Adherium | A new frontier in respirat
Slide 16: 1/3 >80% adherence, 67% average adherence
These adherence levels Reduction to the Risk of Hospitalisations strongly suggest that it Based on Levels of Adherence in COPD could cut hospitalisations 80-100% by half for patients with Adherence 51% COPD 60-80% Nearly one-third of iCARE patients Adherence 48% sustained >80% adherence with an over
Slide 17: Sustained adherence over 14+ months
Sustained adherence over 14+ months Where others see drop-off, iCARE patients stay the course – even amongst 70–80-year-olds Long-term adherence levels 80% 70% 60% 64% 67% 50% 40% 30% 20% 28% 10% 22% 0% Foster Study17 iCARE13 Mannino Study18 iCARE13 Asthma Asthma COPD COPD at at 6 months at 14 month
Slide 18: About Intermountain Health (IMH)
About Intermountain Health (IMH) IMH’s goal is to advance its triple aim: improving patient lives, enhancing health outcomes, and lowering healthcare costs Leading US health system with 33 hospitals and 385 clinics Located in Utah, Idaho, Colorado, Nevada, Kansas and Montana Over 250,000 respiratory
Slide 19: In summary, iCARE demonstrated
In summary, iCARE demonstrated A significant Adherence levels Persistent adherence, Even higher improvement in > 60%, associated maintained over persistence amongst adherence (1.5-3x with a 50% reduction 14 months older, most costly industry norms) in hospitalisation risk patients Adherium | A new f
Slide 20: US Payers Could Save Significant Costs
US Payers Could Save Significant Costs
Slide 21: Select Health could unlock significant savings of nearly $60M
Adherence drives savings: IMH’s Payer arm “Select Health” could unlock significant savings of nearly $60M % of COPD patients COPD patients 50% annual cost savings Revenue onboarded enrolled (illustrative) hospitalisations / ED visits @ $70 pp/mo 5% participation 3.3K $30M $3M 10% participation 6.6K
Slide 22: Cigna could save nearly $1B in direct costs
Cigna, national US payer, could save nearly $1B in direct costs with just 10% of its COPD patients; unlocking value for Adherium % of COPD patients COPD patients 50% annual Revenue onboarded enrolled (illustrative) cost savings18 @ $70 pp/mo 5% participation 53K $473M $44M 10% participation 105K $94
Slide 23: Adherium is the only payer-ready respiratory platform
Adherium is the only payer-ready respiratory platform Payers fund what’s proven, covers most patients, and works in the real world without requiring patient and provider behavioural changes Proven Coverage Capability FDA-cleared Works with Tracks adherence most inhalers Real-world Tracks technique e
Slide 24: Operational Proof at the Practice Level
Operational Proof at the Practice Level Massive payer upside starts with today’s proof: a fee-for-service model building a scalable playbook
Slide 25: Building experience with 4000 active patients EOY
Building experience with 4000 active patients EOY using Adherium’s technology Access to 1M+ Respiratory Patients US Health Medical Groups System Payer/ Remote Patient Partner Providers Monitoring (RPM) Programs • Current mix of device sales (IMH) • HCPs earn FFS from US payers • Current mix of devic
Slide 26: Onboarding/Clinical Care infrastructure established and scalable
Onboarding/Clinical Care infrastructure established and scalable Medical Groups/RPM Partners Eligibility/Coverage Contact/Consent CALL CENTER >2300 active patients today* Product Shipped/Activation • Call Center Model (launched August 2025): ONBOARDING streamlined lead processing at scale • Steep gr
Slide 27: Explosive growth underway: practice partnerships and hospital programs
Explosive growth underway: strong momentum unlocked by practice partnerships and hospital programs Projected to reach 10K active patients 12,000 by Dec 2026 with current partners • Established infrastructure in RPM 8,000 channel demonstrating growth 155% Total QoQ growth • 2300 active patients today
Slide 28: Adherium is poised to transform respiratory care
Adherium is poised to transform respiratory care COMPELLING ESTABLISHED CRITICAL MASS US PAYER COST SAVINGS INFRASTRUCTURE EXPERIENCE READY IMH data Scalable 4000 active patients EOY positioned to unleash cost savings ✓ ✓ 10K patients expected by 2026 Q4 ‘26 Adherium | A new frontier in respiratory
Slide 29: Summary: Adherium is the only payer-ready respiratory platform
Summary: Adherium is the only payer-ready respiratory platform IMH’s iCare program These adherence levels Reductions in costs Adherium now has the demonstrates that are likely to drive could save payers proven technology gathering data improved patient significant amounts and established insights wi
Slide 30: Thank You
Thank You